Innate and Sobi partnership becomes effective after closing conditions
Innate Pharma said its previously announced strategic partnership with Sobi is now effective after applicable antitrust waiting periods expired and other closing conditions were completed.
Story updates
08:00:46 PM UTC
SquawkNews
Innate Pharma said its strategic partnership with Sobi is now effective, triggering a $75M upfront payment and initiating the TELLOMAK-3 Phase 3 study, with first patient expected in Q1 2027.Material DetailsContext by AI AnalystThis is a late confirmation of a previously announced deal, now de-risk…
Innate Pharma SA said its previously announced strategic partnership with Sobi is now effective after the applicable antitrust waiting periods expired and other conditions were completed.